

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D

OMB APPROVAL	
OMB Number:	3235-0076
Estimated average burden hours per response:	4.00

Notice of Exempt Offering of Securities

1. Issuer's Identity

CIK (Filer ID Number)

[0001541157](#)

Name of Issuer

[Akari Therapeutics Plc](#)

Jurisdiction of Incorporation/Organization

[UNITED KINGDOM](#)

Year of Incorporation/Organization

Over Five Years Ago

Within Last Five Years (Specify Year)

Yet to Be Formed

Previous Names

None

[Celsus Therapeutics Plc.](#)

[Morria Biopharmaceuticals PLC](#)

Entity Type

Corporation

Limited Partnership

Limited Liability Company

General Partnership

Business Trust

Other (Specify)

Public Limited Company

2. Principal Place of Business and Contact Information

Name of Issuer

[Akari Therapeutics Plc](#)

Street Address 1

[401 EAST JACKSON STREET](#)

City

[TAMPA](#)

State/Province/Country

[FLORIDA](#)

Street Address 2

[SUITE 3300](#)

ZIP/PostalCode

[33602](#)

Phone Number of Issuer

[\(929\) 274-7510](#)

3. Related Persons

Last Name

[Gaslightwala](#)

Street Address 1

[Akari Therapeutics, Plc](#)

City

[TAMPA](#)

First Name

[Abizer](#)

Street Address 2

[401 East Jackson, Street Suite 3300](#)

State/Province/Country

[FLORIDA](#)

Middle Name

ZIP/PostalCode

[33602](#)

Relationship: Executive Officer Director Promoter

Clarification of Response (if Necessary):

[President and Chief Executive Officer](#)

Last Name

[Farag](#)

Street Address 1

[Akari Therapeutics, Plc](#)

City

[TAMPA](#)

First Name

[Kameel](#)

Street Address 2

[401 East Jackson, Street Suite 3300](#)

State/Province/Country

[FLORIDA](#)

Middle Name

ZIP/PostalCode

[33602](#)

Relationship: Executive Officer Director Promoter

Clarification of Response (if Necessary):

[Interim Chief Financial Officer](#)

Last Name

[Bazemore](#)

Street Address 1

[Akari Therapeutics, Plc](#)

City

[TAMPA](#)

First Name

[Rob](#)

Street Address 2

[401 East Jackson, Street Suite 3300](#)

State/Province/Country

[FLORIDA](#)

Middle Name

ZIP/PostalCode

[33602](#)

Relationship: Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Huh	Hoyoung	
Street Address 1	Street Address 2	
Akari Therapeutics, Plc	401 East Jackson, Street Suite 3300	
City	State/Province/Country	ZIP/PostalCode
TAMPA	FLORIDA	33602
Relationship: <input type="checkbox"/> Executive Officer <input checked="" type="checkbox"/> Director <input type="checkbox"/> Promoter		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Neal	Jim	
Street Address 1	Street Address 2	
Akari Therapeutics, Plc	401 East Jackson, Street Suite 3300	
City	State/Province/Country	ZIP/PostalCode
TAMPA	FLORIDA	33602
Relationship: <input type="checkbox"/> Executive Officer <input checked="" type="checkbox"/> Director <input type="checkbox"/> Promoter		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Prudo	Ray	
Street Address 1	Street Address 2	
Akari Therapeutics, Plc	401 East Jackson, Street Suite 3300	
City	State/Province/Country	ZIP/PostalCode
TAMPA	FLORIDA	33602
Relationship: <input type="checkbox"/> Executive Officer <input checked="" type="checkbox"/> Director <input type="checkbox"/> Promoter		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Patel	Samir	
Street Address 1	Street Address 2	
Akari Therapeutics, Plc	401 East Jackson, Street Suite 3300	
City	State/Province/Country	ZIP/PostalCode
TAMPA	FLORIDA	33602
Relationship: <input type="checkbox"/> Executive Officer <input checked="" type="checkbox"/> Director <input type="checkbox"/> Promoter		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Patel	Sandip	
Street Address 1	Street Address 2	
Akari Therapeutics, Plc	401 East Jackson, Street Suite 3300	
City	State/Province/Country	ZIP/PostalCode
TAMPA	FLORIDA	33602
Relationship: <input type="checkbox"/> Executive Officer <input checked="" type="checkbox"/> Director <input type="checkbox"/> Promoter		

Clarification of Response (if Necessary):

4. Industry Group

- | | | |
|---|---|---|
| <input type="checkbox"/> Agriculture | <input type="checkbox"/> Health Care | <input type="checkbox"/> Retailing |
| <input type="checkbox"/> Banking & Financial Services | <input type="checkbox"/> Biotechnology | <input type="checkbox"/> Restaurants |
| <input type="checkbox"/> Commercial Banking | <input type="checkbox"/> Health Insurance | <input type="checkbox"/> Technology |
| <input type="checkbox"/> Insurance | <input type="checkbox"/> Hospitals & Physicians | <input type="checkbox"/> Computers |
| <input type="checkbox"/> Investing | <input type="checkbox"/> Pharmaceuticals | <input type="checkbox"/> Telecommunications |
| <input type="checkbox"/> Investment Banking | <input checked="" type="checkbox"/> Other Health Care | <input type="checkbox"/> Other Technology |
| <input type="checkbox"/> Pooled Investment Fund | <input type="checkbox"/> Manufacturing | <input type="checkbox"/> Travel |
| Is the issuer registered as | | |

an investment company under the Investment Company Act of 1940?

Yes No

Other Banking & Financial Services

Business Services

Energy

Coal Mining

Electric Utilities

Energy Conservation

Environmental Services

Oil & Gas

Other Energy

Real Estate

Commercial

Construction

REITS & Finance

Residential

Other Real Estate

Airlines & Airports

Lodging & Conventions

Tourism & Travel Services

Other Travel

Other

5. Issuer Size

Revenue Range

OR

Aggregate Net Asset Value Range

No Revenues

\$1 - \$1,000,000

\$1,000,001 - \$5,000,000

\$5,000,001 - \$25,000,000

\$25,000,001 - \$100,000,000

Over \$100,000,000

Decline to Disclose

Not Applicable

No Aggregate Net Asset Value

\$1 - \$5,000,000

\$5,000,001 - \$25,000,000

\$25,000,001 - \$50,000,000

\$50,000,001 - \$100,000,000

Over \$100,000,000

Decline to Disclose

Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))

Rule 504 (b)(1)(i)

Rule 504 (b)(1)(ii)

Rule 504 (b)(1)(iii)

Rule 506(b)

Rule 506(c)

Securities Act Section 4(a)(5)

Investment Company Act Section 3(c)

Section 3(c)(1)

Section 3(c)(2)

Section 3(c)(3)

Section 3(c)(4)

Section 3(c)(5)

Section 3(c)(6)

Section 3(c)(7)

Section 3(c)(9)

Section 3(c)(10)

Section 3(c)(11)

Section 3(c)(12)

Section 3(c)(13)

Section 3(c)(14)

7. Type of Filing

New Notice Date of First Sale 2026-05-20 First Sale Yet to Occur

Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes No

9. Type(s) of Securities Offered (select all that apply)

Equity

Debt

Option, Warrant or Other Right to Acquire Another Security

Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security

Pooled Investment Fund Interests

Tenant-in-Common Securities

Mineral Property Securities

Other (describe)

American Depositary Shares (ADSs), each representing 80,000 Ordinary Shares

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?

Yes No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

Recipient Paulson Investment Company, LLC (Associated) Broker or Dealer <input checked="" type="checkbox"/> None None	Recipient CRD Number <input type="checkbox"/> None 000005670 (Associated) Broker or Dealer CRD Number <input checked="" type="checkbox"/> None None	
Street Address 1 150 2nd Avenue, North	Street Address 2 Suite 1550	
City St. Petersburg	State/Province/Country FLORIDA	ZIP/Postal Code 33701
State(s) of Solicitation (select all that apply) Check "All States" or check individual States <input type="checkbox"/> All States <input type="checkbox"/> Foreign/non-US		
<input type="checkbox"/> ARIZONA <input type="checkbox"/> FLORIDA		

13. Offering and Sales Amounts

Total Offering Amount \$5,500,000 USD or Indefinite
Total Amount Sold \$1,833,333 USD
Total Remaining to be Sold \$3,666,667 USD or Indefinite

Clarification of Response (if Necessary):

Offering of ADSs, Pre-Funded Warrants, Series H, I and J Warrants, each convertible into one ADS for \$5,500,000. Approximately \$1,833,333 raised to date. The issuance of Series Warrants are subject to shareholder approval.

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. _____
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$125,000 USD Estimate
Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

Paulson is also entitled to a fee equal to 2.0% of the gross proceeds, a non-accountable expense of \$15,000, and 117,647 Placement Agent ADSs. The issuance of the Placement Agent ADSs are subject to receipt of shareholder approval.

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

The Company intends to use the net proceeds for working capital and general corporate purposes.

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them,

upon written request, in the accordance with applicable law, the information furnished to offerees.*

- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Akari Therapeutics Plc	/s/ Abizer Gaslightwala	Abizer Gaslightwala	Chief Executive Officer and President	2026-06-03

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.